{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=brca2+Gene+Mutation", "query": { "condition": "brca2 Gene Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 112, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=brca2+Gene+Mutation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T14:05:30.227Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03943173", "title": "Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "BRCA-Mutated Ovarian Carcinoma", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "High Grade Fallopian Tube Serous Adenocarcinoma", "High Grade Ovarian Serous Adenocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2019-06-07", "completion_date": "2027-06-27", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03943173" }, { "nct_id": "NCT02993068", "title": "Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BARD1 Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "BRIP1 Gene Mutation", "Estrogen Receptor Negative", "HER2/Neu Negative", "MLH1 Gene Mutation", "MSH2 Gene Mutation", "MSH6 Gene Mutation", "PALB2 Gene Mutation", "PMS2 Gene Mutation", "Progesterone Receptor Negative", "RAD51C Gene Mutation", "RAD51D Gene Mutation", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Genetic Counseling", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "FEMALE", "summary": "30 Years and older · Female only" }, "enrollment_count": 5200, "start_date": "2017-04-18", "completion_date": "2026-04-18", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02993068" }, { "nct_id": "NCT01078662", "title": "Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian", "Breast", "Prostate", "Pancreatic", "Advanced Tumours" ], "interventions": [ { "name": "olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 298, "start_date": "2010-02-21", "completion_date": "2024-08-12", "has_results": true, "last_update_posted_date": "2025-08-13", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 2, "location_summary": "West Hollywood, California • Philadelphia, Pennsylvania", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01078662" }, { "nct_id": "NCT01097278", "title": "S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "brca1 Mutation Carrier", "brca2 Mutation Carrier", "Breast Cancer" ], "interventions": [ { "name": "cholecalciferol", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 208, "start_date": "2011-11-01", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 360, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 230 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01097278" }, { "nct_id": "NCT05054725", "title": "Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "RMC-4630", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-12-30", "completion_date": "2024-08-29", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 23, "location_summary": "Fort Myers, Florida • Plantation, Florida • Saint Augustine, Florida + 20 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Saint Augustine", "state": "Florida" }, { "city": "Evergreen Park", "state": "Illinois" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054725" }, { "nct_id": "NCT02985658", "title": "Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation", "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Veliparib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2021-07-21", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02985658" }, { "nct_id": "NCT04030559", "title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ATM Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "BRIP1 Gene Mutation", "CDK12 Gene Mutation", "CHEK1 Gene Mutation", "CHEK2 Gene Mutation", "DNA Damage Response Gene Mutation", "DNA Repair Gene Mutation", "FANCA Gene Mutation", "FANCD2 Gene Mutation", "FANCL Gene Mutation", "GEN1 Gene Mutation", "NBN Gene Mutation", "Prostate Carcinoma", "RAD51 Gene Mutation", "RAD51C Gene Mutation" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Niraparib Tosylate Monohydrate", "type": "DRUG" }, { "name": "Radical Prostatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2020-02-25", "completion_date": "2025-11-07", "has_results": true, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04030559" }, { "nct_id": "NCT06127979", "title": "A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "core needle biopsy", "type": "PROCEDURE" }, { "name": "blood draw", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2024-08-30", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06127979" }, { "nct_id": "NCT05129605", "title": "Prostate Cancer Genetic Risk Evaluation and Screening Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasm", "Prostate Cancer", "BRCA2 Mutation", "BRCA1 Mutation", "ATM Gene Mutation", "MMR Mutation", "Lynch Syndrome", "Genetic Predisposition to Disease" ], "interventions": [ { "name": "Prostate cancer screening", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "74 Years", "sex": "MALE", "summary": "35 Years to 74 Years · Male only" }, "enrollment_count": 400, "start_date": "2020-02-12", "completion_date": "2040-12", "has_results": false, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05129605" }, { "nct_id": "NCT01233505", "title": "Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Stomach", "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Ovarian Mucinous Cystadenocarcinoma", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Gastric Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "veliparib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-07-22T14:05:30.227Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01233505" } ] }